Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00443287 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral Arterial Disease
A Phase 2 study of Intermittent Claudication, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 553
- Enrollment target
- 7
- Study locations
NCT00443287: Completed Phase 2 study of Intermittent Claudication, sponsored by Sanofi.
NCT00443287 is a Phase 2 study of Intermittent Claudication that has completed, run by Sanofi. The registered enrollment target is 553 participants, above the 166-participant average among 11 other Intermittent Claudication trials with a reported enrollment target (233% higher). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00443287, a Phase 2 study of Intermittent Claudication, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 553 participants
- Enrollment target
- 7
- Study locations
Study Summary
The primary objective is to investigate in patients suffering from intermittent claudication due to Fontaine stage II Peripheral Arterial Disease (PAD) whether a 26-week treatment by HMR1766 on top of clopidogrel may result in an improvement of walking capacity, by comparing three doses of HMR1766 to placebo, and calibrating such effect versus cilostazol.
Conditions Studied
Interventions
- DRUG placebo
- DRUG ataciguat (HMR1766)
- DRUG cilostazol
Study Locations (7)
Other
- Sanofi-Aventis Administrative Office - Vienna
- Sanofi-Aventis Administrative Office - Laval
- Sanofi-Aventis Administrative Office - Paris
- Sanofi-Aventis Administrative Office - Warsaw
- Sanofi-Aventis Administrative Office - Moscow
- Sanofi-Aventis Administrative Office - Midrand
New Jersey
- Sanofi-Aventis Administrative Office - Bridgewater
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 553 participants |
| Start Date | 2007-02 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
What the finished NCT00443287 record still lists
NCT00443287 is an interventional study that assigns participants to a tested intervention. The registered 553 participants enrollment target is mid-sized for trials with a published cap, above the 166-participant average among 11 other Intermittent Claudication trials with a reported enrollment target (233% higher).
The record links to 1 condition, with Intermittent Claudication appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT00443287 lists 7 locations in 2 states (Other, New Jersey).
Frequently Asked Questions
What is clinical trial NCT00443287 about?
NCT00443287 is a clinical study titled "Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral Arterial Disease". The primary objective is to investigate in patients suffering from intermittent claudication due to Fontaine stage II Peripheral Arterial Disease (PAD) whether a 26-week treatment by HMR1766 on top of clopidogrel may result in an improvement of walking capacity, by comparing three doses of HMR1766 t...
What is the current status of trial NCT00443287?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 553 participants. The study started on 2007-02. Estimated completion is 2008-10.
What conditions does trial NCT00443287 study?
This clinical trial studies the following conditions: Intermittent Claudication.
What interventions are being tested in trial NCT00443287?
The interventions under investigation include: placebo (DRUG), ataciguat (HMR1766) (DRUG), cilostazol (DRUG).
Who is sponsoring clinical trial NCT00443287?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00443287 being conducted?
This trial has 7 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Intermittent Claudication
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00443287's enrollment target sits among peer trials
553 1st of 11 higher than 11 of 11 other Intermittent Claudication trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Intermittent Claudication trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Response to Exercise and Nitric Oxide in PAD
RECRUITING · Phase 2
-
A Phase 2 Study of the Effects of Sapropterin Dihydrochloride on Symptomatic Peripheral Arterial Disease
COMPLETED · Phase 2
-
Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients With Intermittent Claudication
COMPLETED · Phase 2
-
Improving Mobility After Revascularization in Peripheral Artery Disease
RECRUITING · Phase 3
-
MetfOrmin BenefIts Lower Extremities With Intermittent Claudication
RECRUITING · Phase 3
-
The Chocolate Touch Study
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05786924 · 554 participants · Phase 1
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- NCT06217809 · 552 participants · NA
EmpowHer is Prevention Curriculum for Youth Ages 10-15 Years.
- NCT07146022 · 552 participants · Phase 3
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
- NCT06799000 · 555 participants · Phase 3
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia